Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Net Income Loss of -$20.20 million for the year ending 2025.
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -48.7% in Net Income Loss from 2024 to 2025.
- This data is from HERON THERAPEUTICS, INC. /DE/'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), HERON THERAPEUTICS, INC. /DE/'s Net Income Loss has declined by 101.4%.
- Historical annual values: Fiscal year 2025: -$20.20 million | Fiscal year 2024: -$13.58 million | Fiscal year 2023: -$110.56 million | Fiscal year 2022: -$182.02 million | Fiscal year 2021: -$220.68 million | Fiscal year 2020: -$227.28 million | Fiscal year 2019: -$204.75 million | Fiscal year 2018: -$178.84 million | Fiscal year 2017: -$197.48 million | Fiscal year 2016: -$173.14 million | Fiscal year 2015: -$97.59 million | Fiscal year 2014: -$76.37 million | Fiscal year 2013: -$55.28 million | Fiscal year 2012: -$23.35 million | Fiscal year 2011: -$11.81 million | Fiscal year 2010: -$7.35 million | Fiscal year 2009: -$10.03 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: